We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merrimack's (MACK) Reports Wider-than-Expected Q1 Loss
Read MoreHide Full Article
Cambridge, MA-based Merrimack Pharmaceuticals, Inc. (MACK - Free Report) is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies in combination with companion diagnostics for the treatment of cancer.
Merrimack sold its only marketed product, Onivyde, to Ipsen in Jan 2017 through a definitive asset purchase and sale agreement for $1 billion. Merrimack also announced a special cash dividend of $140 million to holders of common stock.
With sale of Onivyde, Merrimack is now a developmental stage company. The company will now focus its resources on the development of its three pipeline candidates – MM-121/seribantumab (heregulin-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC), MM-141/istiratumab (pancreatic cancer) and MM-310 (solid tumor).
Merrimack’s track record has been mixed so far with a four-quarter average positive earnings surprise of 1.86%. The company has beaten estimates twice in the last four trailing quarters while missing twice.
Currently, Merrimack has a Zacks Rank #4 (Sell), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Merrimack reported a wider than expected first-quarter loss. The company reported a loss of 22 cents per share, wider than our consensus estimate of 7 cents.
Revenues: Merrimack did not record any revenues in the quarter due to sale of Onivyde. The consensus estimate stood at $34.8 million.
Key Stats: Research and development expenses were down 22.9% y/y to $21.6 million. General and administrative expenses were down 13.8% y/y to $5.6 million during the quarter.
Share Market Activity: The shares of the company are trading 0.3% down in pre-market.
2017 Guidance: Merrimack expects its current financial resources along with anticipated milestone payments from Shire will be sufficient to fund its operations at currently forecasted spending rates into the second half of 2019.
Merrimack Pharmaceuticals, Inc. Price and EPS Surprise
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Merrimack's (MACK) Reports Wider-than-Expected Q1 Loss
Cambridge, MA-based Merrimack Pharmaceuticals, Inc. (MACK - Free Report) is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies in combination with companion diagnostics for the treatment of cancer.
Merrimack sold its only marketed product, Onivyde, to Ipsen in Jan 2017 through a definitive asset purchase and sale agreement for $1 billion. Merrimack also announced a special cash dividend of $140 million to holders of common stock.
With sale of Onivyde, Merrimack is now a developmental stage company. The company will now focus its resources on the development of its three pipeline candidates – MM-121/seribantumab (heregulin-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC), MM-141/istiratumab (pancreatic cancer) and MM-310 (solid tumor).
Merrimack’s track record has been mixed so far with a four-quarter average positive earnings surprise of 1.86%. The company has beaten estimates twice in the last four trailing quarters while missing twice.
Currently, Merrimack has a Zacks Rank #4 (Sell), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Merrimack reported a wider than expected first-quarter loss. The company reported a loss of 22 cents per share, wider than our consensus estimate of 7 cents.
Revenues: Merrimack did not record any revenues in the quarter due to sale of Onivyde. The consensus estimate stood at $34.8 million.
Key Stats: Research and development expenses were down 22.9% y/y to $21.6 million. General and administrative expenses were down 13.8% y/y to $5.6 million during the quarter.
Share Market Activity: The shares of the company are trading 0.3% down in pre-market.
2017 Guidance: Merrimack expects its current financial resources along with anticipated milestone payments from Shire will be sufficient to fund its operations at currently forecasted spending rates into the second half of 2019.
Merrimack Pharmaceuticals, Inc. Price and EPS Surprise
Merrimack Pharmaceuticals, Inc. Price and EPS Surprise | Merrimack Pharmaceuticals, Inc. Quote
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>